Research Grant Program 2017-09-12T15:49:53+00:00

Research Grant Program

The Cure RTD Foundation (CureRTD) and its international affiliates announce the availability of funding for basic science and clinical research on the natural history, biochemical basis, and treatment of Riboflavin Transporter Deficiency (RTD).

There are two basic categoriesIDEA grants for 1-2 years and DEVELOPMENT grants for 2-3 years with budgetary maximums of US $50,000 or $100,000, respectively. Although CureRTD will consider any research proposal related to RTD, it is particularly interested in supporting research in the areas identified by REQUEST FOR APPLICATION (RFAs).  RFAs for work in clinical/scientific areas that CureRTD considers to be high priority areas of investigation may have increased budgetary maximums and other requirements. Applications responding to RFAs will be given preferential consideration in the Cure RTD Research Grant Program.

We encourage investigators at all professional levels to submit their best ideas. There are no geographical limitations to this funding.


Riboflavin transporter deficiency (RTD), formerly known as Brown-Vialetto-van Laere (BVVL) and Fazio Londe (FL) syndrome, is an early-onset neurodegenerative disorder with distinctive phenotypes. RTD is caused by mutations in either the SLC52A2 or SLC52A3 genes that encode riboflavin transporters RFVT-2 and RFVT-3, respectively.  The disease is characterized by motor neuronopathy (manifest as proximal and distal limb weakness, often with severe distal wasting and breathing problems due to paralysis of the diaphragm), sensory neuronopathy, and cranial neuronopathy (manifest as auditory neuropathy,  pontobulbar palsy and optic atrophy).  Treatment with riboflavin has recently been found to ameliorate symptoms in many patients but research is required to both better understand optimal flavin treatment strategies and develop complementary novel therapeutic strategies.  Because many clinical and biochemical abnormalities of RTD remain poorly understood, we are seeking proposals for both basic science and clinical research that may shed light on any aspect of the syndrome with the object of developing advancing current treatment or a cure.

Types of Proposals Sought

We are interested in providing “seed grant funding” to young investigators as well as attracting experienced investigators new to the field of RTD basic science or clinical research. We anticipate that these funds will be used for the testing of initial hypotheses and the collection of preliminary data leading to successful long-term funding by the National Institutes of Health (NIH) and other major granting institutions around the world.


CureRTD has a competitive grant process. In general terms, detailed information about the specific aims, significance, research design and methods, personnel, facilities, and budget will be required. A one-page, “Letter of Intent” is required for DEVELOPMENT grant applicants. The “Letter of Intent” is optional for IDEA grant applicants. We strongly encourage the submission of letters of intent before the due date to allow ample time.

Completed applications (and/or “letters of intent”) will be forwarded to the CureRTD Scientific and Medical Advisory Board (as well as to expert outside reviewers) for confidential evaluation. Response to the “Letter of Intent” will be communicated within two weeks of receipt. Based on the recommendations of the CureRTD Scientific and Medical Advisory Board, the CureRTD Board of Directors will make the final funding decisions about the grant applications. Once the final funding decisions are made, CureRTD affiliates will decide which, if any, of the approved grants they would like to fund.


We anticipate awarding several IDEA and DEVELOPMENT grants each year. Funds will be available soon after the successful grant applicants have been notified.

Contact Information

Keith Massey
Science Director
Cure RTD Foundation
Local Line:  403-244-4549